Compare
Side by side
Pick up to three peptides to see how their mechanisms, studied uses and evidence levels differ. Rows where the entries disagree are marked with a blue edge.
Selected 1 of 3
Comparison
ARA-290 (cibinetide)
Immune
Evidence level
Limited evidence
Approval status
Investigational
Mechanism of action
- 1.Binds the innate repair receptor, a complex formed by the erythropoietin receptor and its partner CD131.
- 2.That receptor is involved in tissue-protective signalling rather than red-blood-cell production, so it does not raise haematocrit like erythropoietin.
- 3.Reduces inflammatory cytokine signalling in laboratory models.
- 4.Protects nerve tissue in animal models of neuropathy.
- 5.Clinical trials in people have not translated these findings into consistent benefit.
Studied for
- Sarcoidosis-associated small-fibre neuropathy
- Diabetic peripheral neuropathy
- Inflammatory and tissue-protective pathways
- Type 2 diabetes complications (early trials)
Reported effects
- Improved small-nerve function measures in early trials
- Reduced inflammatory markers in some studies
- Reported reduced pain from user accounts
- No confirmed effect on wound healing in humans
Side effects
- Injection-site reactions
- Headache
- Transient increases in inflammatory markers in some patients
- Long-term safety unknown
Research protocol
Research context only — no approved protocol exists. Trials used daily subcutaneous doses in the 2–4 mg range for 4–12 weeks in sarcoidosis-associated small-fibre neuropathy and diabetic neuropathy. Outcomes were mixed and the compound has not progressed to approval; self-administered regimens sold online have no evidence base.
Research context only
Evidence justification
Phase 1 and small phase 2 trials exist in sarcoidosis and diabetic nerve pain with mixed results; nothing is approved and larger trials have not confirmed benefit.